Back to Search
Start Over
CYP1A2*F Polymorphism Contributes at Least Partially to the Variability of Plasma Levels of Dehydroaripiprazole, an Active Metabolite of Aripiprazole, in Schizophrenic Patients.
- Source :
-
Drug metabolism and bioanalysis letters [Drug Metab Bioanal Lett] 2024; Vol. 17 (1), pp. 7-12. - Publication Year :
- 2024
-
Abstract
- Aim: The relationship between CYP1A2 polymorphisms and the steady-state plasma levels of aripiprazole and its active metabolite, dehydroaripiprazole, were investigated in Japanese schizophrenic patients.<br />Background: It has been implied that cytochrome P450 (CYP) 1A2 may play a role in the metabo-lism of aripiprazole. Genetic variations in the CYP1A2 gene have been reported.<br />Objective: The authors investigated the relationship between 2 CYP1A2 polymorphisms, CYP1A2*C (-3860G>A) and CYP1A2*F (-163C>A) , and the steady-state plasma levels/dose (C/D) ratios of aripiprazole and dehydroaripiprazole in Japanese schizophrenic patients.<br />Methods: All 89 subjects (46 males and 43 females) had been receiving 2 fixed daily doses of aripiprazole (24 mg; n=56 and 12 mg: n=33) for more than 2 weeks. No other drugs were used except flunitrazepam and biperiden. The plasma drug levels were determined by LC/MS/MS. These CYP1A2 polymorphisms were detected using polymerase chain reaction analysis.<br />Results: The mean C/D ratios of dehydroaripiprazole were significantly (P < 0.05) lower in patients with the A/A allele of CYP1A2*F than in those without the allele. No differences were found in the values of aripiprazole and the combination of aripiprazole and dehydroaripiprazole among the CYP1A2 *F genotype. There were no differences in the values of aripiprazole, dehydroaripiprazole, or the combination of the 2 compounds among the CYP1A2 *C genotype. The absence of the A allele of CYP1A2 *F was correlated with the mean C/D ratios of dehydroaripiprazole (standardized partial correlation coefficient = 0.276, P < 0.01) by multiple regression analysis.<br />Conclusion: The findings of this study suggest that the CYP1A2 *F polymorphism contributes at least partially to the variability in the steady-state plasma levels of dehydroaripiprazole.<br /> (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Subjects :
- Adult
Female
Humans
Male
Middle Aged
Genotype
Polymorphism, Genetic genetics
East Asian People
Japan
Antipsychotic Agents blood
Antipsychotic Agents pharmacokinetics
Antipsychotic Agents therapeutic use
Aripiprazole blood
Aripiprazole pharmacokinetics
Cytochrome P-450 CYP1A2 genetics
Cytochrome P-450 CYP1A2 metabolism
Piperazines blood
Piperazines pharmacokinetics
Piperazines therapeutic use
Quinolones blood
Quinolones pharmacokinetics
Schizophrenia drug therapy
Schizophrenia genetics
Schizophrenia blood
Subjects
Details
- Language :
- English
- ISSN :
- 2949-6829
- Volume :
- 17
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Drug metabolism and bioanalysis letters
- Publication Type :
- Academic Journal
- Accession number :
- 37855290
- Full Text :
- https://doi.org/10.2174/0118723128246698230921095141